Literature DB >> 16887444

Congenital localized scleroderma.

Francesco Zulian1, Cristina Vallongo, Sheila Knupp Feitosa de Oliveira, Marilynn G Punaro, Joan Ros, Henryka Mazur-Zielinska, Paul Galea, Liviana Da Dalt, Lawrence F Eichenfield.   

Abstract

OBJECTIVES: Juvenile localized scleroderma (JLS) usually has its onset during later childhood. This report describes the clinical and serologic features of six children with congenital localized scleroderma (CLS). STUDY
DESIGN: A large, multinational study was conducted among pediatric rheumatology and dermatology centers by collecting information on demographics, family history, triggering environmental factors, clinical features, laboratory reports, and treatment of patients with JLS. Patients with onset at birth were carefully examined.
RESULTS: Among 750 patients with JLS, 6 patients (0.8%) had scleroderma-related lesions at birth. Female-to-male ratio was 2:1. All patients had linear scleroderma, in four involving the face with en coup de sabre appearance. Two patients were misdiagnosed as having skin infection, one nevus, one salmon patch, and two undefined skin lesions. The mean diagnostic delay was 3.9 years. In comparison with the group of 733 patients with late-onset JLS, CLS presented a significantly more prolonged disease duration at diagnosis and a higher frequency of en coup de sabre subtypes.
CONCLUSIONS: Congenital localized scleroderma is a rare and probably underestimated condition in neonates. The linear subtype was the exclusive manifestation of the disease. CLS should be included in the differential diagnosis of infants with cutaneous erythematous fibrotic lesions to avoid functional and aesthetic sequelae and to allow prompt therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16887444     DOI: 10.1016/j.jpeds.2006.04.052

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  6 in total

1.  [Localized scleroderma (morphea) in childhood].

Authors:  L Weibel
Journal:  Hautarzt       Date:  2012-02       Impact factor: 0.751

2.  Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma.

Authors:  Suzanne C Li; Kathryn S Torok; Elena Pope; Fatma Dedeoglu; Sandy Hong; Heidi T Jacobe; C Egla Rabinovich; Ronald M Laxer; Gloria C Higgins; Polly J Ferguson; Andrew Lasky; Kevin Baszis; Mara Becker; Sarah Campillo; Victoria Cartwright; Michael Cidon; Christi J Inman; Rita Jerath; Kathleen M O'Neil; Sheetal Vora; Andrew Zeft; Carol A Wallace; Norman T Ilowite; Robert C Fuhlbrigge
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-08       Impact factor: 4.794

Review 3.  Pediatric scleroderma: systemic or localized forms.

Authors:  Kathryn S Torok
Journal:  Pediatr Clin North Am       Date:  2012-04-06       Impact factor: 3.278

4.  Morphea with Oral Mucosa Involvement and Unilateral Nevoid Telangiectasia as an Early Presentation of Morphea: A Case Report and Review of the Literature.

Authors:  Penelope Hirt; Suchismita Paul; Weena Phuthongkam; Lawrence Schachner
Journal:  J Clin Aesthet Dermatol       Date:  2020-01-01

5.  Consensus-based recommendations for the management of juvenile localised scleroderma.

Authors:  Francesco Zulian; Roberta Culpo; Francesca Sperotto; Jordi Anton; Tadej Avcin; Eileen M Baildam; Christina Boros; Jeffrey Chaitow; Tamàs Constantin; Ozgur Kasapcopur; Sheila Knupp Feitosa de Oliveira; Clarissa A Pilkington; Ricardo Russo; Natasa Toplak; Annet van Royen; Claudia Saad Magalhães; Sebastiaan J Vastert; Nico M Wulffraat; Ivan Foeldvari
Journal:  Ann Rheum Dis       Date:  2019-03-02       Impact factor: 19.103

6.  A cross-sectional electromyography assessment in linear scleroderma patients.

Authors:  Claudia Saad Magalhães; Taciana de Albuquerque Pedrosa Fernandes; Thiago Dias Fernandes; Luis Antonio de Lima Resende
Journal:  Pediatr Rheumatol Online J       Date:  2014-07-12       Impact factor: 3.054

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.